Articles from Libra Th.erapeutics, Inc

Libra Therapeutics, Inc., (“Libra”) a private biotechnology company developing novel disease-modifying therapeutics to restore cellular homeostasis and slow the progression of neurodegenerative diseases, today announced the promotion of Martin (Marty) Gill, Ph.D., to Chief Scientific Officer. Dr. Gill, who previously served as Senior Vice President and Head of Research, has been instrumental in shaping Libra’s scientific strategy and advancing its therapeutic programs targeting autophagy and lysosomal function. As CSO, Dr. Gill will continue to lead Libra’s research efforts to develop innovative small molecule therapies for neurodegenerative diseases with high unmet medical need, including amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).